North American Hidradenitis Suppurativa Foundation
North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations
Read the guideline
Abstract
Hidradenitis suppurativa (HS) affects different patient populations that require unique considerations in their management. However, no HS guidelines for these populations exist.
To provide evidence-based consensus recommendations for patients with HS in 7 special patient populations: (i) pregnancy, (ii) breastfeeding, (iii) pediatrics, (iv) malignancy, (v) tuberculosis infection, (vi) hepatitis B or C infection, and (vii) HIV disease.
More in dermatology
- Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsNational Psoriasis Foundation Medical Board and the International Psoriasis Council · 2026
- Generalized Pustular Psoriasis: Review and Consensus of the Psoriasis Group of the Spanish Academy of Dermatology and VenereologySpanish Academy of Dermatology and Venereology · 2026
